ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
62,964.00
-1.22%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. Actinium Pharmaceuticals Inc (ATNM)

  7. Actinium Pharmaceuticals Inc (ATNM) Noticias

ATNM Actinium Pharmaceuticals Inc

6.80
0.24 (3.66%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Actinium Pharmaceuticals Inc ATNM AMEX Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.24 3.66% 6.80 17:56:02
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
6.58 6.485 6.92 6.87 6.56
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
18/4/202407:00PRNUSActinium Highlights Ability of Iomab-B to Overcome High-Risk..
01/4/202407:00PRNUSActinium Announces Iomab-B Phase 3 SIERRA Trial Results..
26/3/202406:18PRNUSActinium Announces Clinical Trial to Study Iomab-ACT..
11/3/202406:30PRNUSActinium Pharmaceuticals Launches Actinium-225 Focused..
26/2/202406:30PRNUSActinium Announces Iomab-B Markedly Increases Long Term..
23/2/202406:30PRNUSActinium Highlights Improved Survival with Iomab-B in TP53..
09/2/202415:30EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
05/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
02/2/202416:03EDGAR2Form S-3/A - Registration statement under Securities Act of..
02/1/202406:30PRNUSActinium Announces Acceptance of Five Abstracts for..
29/12/202316:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202316:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202316:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202316:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/12/202316:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202307:15PRNUSActinium Announces Iomab-B Produces High Response Rates and..
11/12/202306:45PRNUSActinium's Four Presentations at ASH Highlight the Positive..
08/12/202307:00PRNUSActinium to Highlight Broad Potential of Targeted..
01/12/202316:00EDGAR2Form 8-K - Current report
09/11/202316:05EDGAR2Form DEF 14A - Other definitive proxy statements
06/11/202306:30PRNUSActinium Presents Preclinical Data at SITC Demonstrating..
02/11/202315:15PRNUSActinium Pharmaceuticals to Attend Bio-Europe Munich 2023
02/11/202308:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202308:05PRNUSActinium Announces Oral Presentation at ASH Annual Meeting..
04/10/202306:30PRNUSActinium Announces NIH Grant Extension to Advance Clinical..
27/9/202308:05PRNUSActinium Pharma Highlights Abstract Accepted for Poster..
07/9/202307:40PRNUSActinium Pharma Presents Survival Data from Extended..
31/8/202306:00PRNUSActinium Pharma Highlights Three Abstracts Accepted for..
21/8/202306:00PRNUSActinium Pharma Highlights Abstracts Accepted for Oral and..
14/8/202316:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202308:00EDGAR2Form S-3 - Registration statement under Securities Act of..
24/7/202306:00PRNUSActinium Pharma to Present at the 2nd Annual Targeted..
26/6/202306:00PRNUSSNMMI 2023 Annual Meeting Abstract of the Year Awarded to..
23/6/202307:00PRNUSActinium Pharma Highlights Six Abstracts Accepted for Oral..
16/6/202306:00PRNUSActinium Pharma to Present at the Maxim Healthcare Virtual..
14/6/202306:00PRNUSActinium Pharma to Present at the TD Cowen..
12/6/202306:00PRNUSActinium Announces Positive Pivotal Phase 3 SIERRA Trial..
07/6/202306:00PRNUSActinium Pharma Set to Join Russell 2000® and Russell 3000®..
22/5/202306:00PRNUSActinium Pharma Announces Six Abstracts Accepted for Oral..
11/5/202310:18PRNUSActinium Pharma Announces Iomab-B SIERRA Trial Results..
10/5/202306:00PRNUSActinium Pharma to Present at Guggenheim Healthcare Talks..
28/4/202307:00PRNUSActinium Highlights Successful Administration of Targeted..

Su Consulta Reciente

AMEX
ATNM
Actinium Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados